Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: A propensity-score matching analysis

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Koie, Takuya ^a   Ohyama, Chikara ^a   Yamamoto, Hayato ^a   Imai, Atsushi ^a   Hatakeyama, Shingo ^a   Yoneyama, Takahiro ^a   Hashimoto, Yasuhiro ^a   Yoneyama, Tohru ^a   Tobisawa, Yuki ^a   Aoki, Masahiko ^a   Takai, Yoshihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Biochemical outcomes; Propensity score matching; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

ANDROGEN; ESTRAMUSTINE PHOSPHATE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRAMUSTINE; GONADORELIN;

ADJUVANT THERAPY; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; COMPUTER ASSISTED RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROPENSITY SCORE; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; ADENOCARCINOMA; AGONISTS; CANCER STAGING; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION DOSE; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; ESTRAMUSTINE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPENSITY SCORE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84900336605     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-134     Document Type: Article

References (18)

1. Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV. Death from high-risk prostate cancer versus cardiovascular mortality with hormone therapy. Cancer 2013, 119:1808-1815. 10.1002/cncr.27980, 23400678.
2. Hoffman RM, Koyama T, Kang-Hsien F, Albertsen PC, Barry MJ, Goodman M, Hamilton AS, Potosky AL, Stanford JL, Stroup AM, Penson DF. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst 2013, 105:711-718. 10.1093/jnci/djt059, 23615689.
3. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011, 59:88-95. 10.1016/j.eururo.2010.10.003, 20965646.
4. Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol 2012, 19:836-844. 10.1111/j.1442-2042.2012.03052.x, 22574746.
5. Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, Deasy JO, Michalski JM, Kallogjeri D, Piccirillo JF, Rabah DM, Yu C, Kattan MW, Stephenson AJ. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012, 187:1259-1265. 10.1016/j.juro.2011.11.084, 22335870.
6. Koie T, Ohyama C, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y, Kamimura N. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study. Prostate Cancer Prostatic Dis 2012, 15:397-401. 10.1038/pcan.2012.29, 22890389.
7. Koie T, Yamamoto H, Hatakeyama S, Kudoh S, Yoneyama T, Hashimoto Y, Kamimura N, Ohyama C. Minimum incision endoscopic radical prostatectomy: clinical and oncological outcomes at a single institute. Eur J Surg Oncol 2011, 37:805-810. 10.1016/j.ejso.2011.06.009, 21782374.
8. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974. 10.1016/j.ijrobp.2006.04.029, 16798415.
9. Rubin DB, Thomas N. Matching estimated propensity scores: relating theory to practice. Biometrics 1996, 52:249-264. 10.2307/2533160, 8934595.
10. AJCC cancer staging manual 2010, New York: Springer, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, 7.
11. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, . ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228-1242. 10.1097/01.pas.0000173646.99337.b1, 16096414, ISUP Grading Committee.
12. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy: results from the prostate cancer results study group. BJU Int 2012, 109:22-29.
13. Walz J, Joniau S, Chun F, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H, Karakiewics PI. Pathological results and rate of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2010, 107:765-770.
14. Xylinas E, Daché A, Roupre{inverted breve}t M. Is radical prostatectomy a viable therapeutic option in clinically locally advanced [T3] prostate cancer?. BJU Int 2010, 106:1596-1600. 10.1111/j.1464-410X.2010.09630.x, 20840545.
15. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A, . Lupron Depot Neoadjuvant Prostate Cancer Study Group Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002, 167:112-116. 10.1016/S0022-5347(05)65393-1, 11743286, Lupron Depot Neoadjuvant Prostate Cancer Study Group.
16. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000, 18:3904-3911.
17. Bolla M, Gonsalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med 1997, 337:295-300.
18. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J Urol 1996, 156:450-453. 10.1016/S0022-5347(01)65876-2, 8683700.